GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sequenom Inc (NAS:SQNM) » Definitions » Other Liabilities for Banks

Sequenom (Sequenom) Other Liabilities for Banks


View and export this data going back to 2000. Start your Free Trial

What is Sequenom Other Liabilities for Banks?

Other Liabilities (Bank) only applies to banks.


Sequenom (Sequenom) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Sequenom Inc was incorporated in 1994 under the laws of the State of Delaware. It is a life science company providing revolutionary genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. It develop and commercialize molecular diagnostics testing services that target and serve molecular diagnostics markets, and also develop and commercialize research use genetic analysis products and services that target and serve discovery and clinical research markets. It offers its services and products in the United States and international emphasis in countries like European and Asia-Pacific regions. The Company operates in two operating segments; Sequenom Laboratories and Sequenom Bioscience. Sequenom Laboratories provides molecular based, laboratory developed tests, or LDTs, with a focus principally on prenatal diseases and conditions and ophthalmological diseases and conditions. Sequenom Bioscience provides technology and research tools for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. The Company's competitors include; Ariosa Diagnostics, Inc., Beijing Genomics Institute, Cellscape Corp., Celula Inc., Ikonysis, Inc., Kellbenx, Inc., Laboratory Corporation of America Holdings, Inc., Natera, Perkin Elmer, Inc., Quest Laboratories, Verinata and others. Its patent portfolio, including in-licensed patent rights, includes approximately 638 issued or allowed patents in the United States and other industrial nations throughout the world. Its prenatal diagnostic patent portfolio includes exclusive rights to numerous in-licensed issued patents. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and chemicals, as well as certain waste products.
Executives
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Kenneth F Buechler director
Charles P Slacik director 250 S. KRAEMER BLVD, BREA CA 92821
Jeffrey D Linton officer: Sr VP, GC & Secretary 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Carolyn Beaver officer: SVP & CFO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Benjamin R Miller director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
William Haas director
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Eberts F Samuel Iii director, officer: Chairman, President & Sec 22 W FRONTAGE ROAD, NORTHFIELD IL 60093
Glenn A Eisenberg director, officer: EVP and Treasurer P O BOX 1017, CHARLOTTE NC 28201-1017
Van Der Vaart Sandra D director 531 SOUTH SPRING STREET, BURLINGTON NC 27215
David Pendarvis director REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Camber Capital Management Lp 10 percent owner 101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
William J Welch officer: President & CEO 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121